ATE259243T1 - Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse - Google Patents
Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasseInfo
- Publication number
- ATE259243T1 ATE259243T1 AT96938773T AT96938773T ATE259243T1 AT E259243 T1 ATE259243 T1 AT E259243T1 AT 96938773 T AT96938773 T AT 96938773T AT 96938773 T AT96938773 T AT 96938773T AT E259243 T1 ATE259243 T1 AT E259243T1
- Authority
- AT
- Austria
- Prior art keywords
- body mass
- lean body
- increase lean
- obesity protein
- increasing
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56173295A | 1995-11-22 | 1995-11-22 | |
| PCT/US1996/017718 WO1997018833A1 (en) | 1995-11-22 | 1996-11-04 | Methods of increasing lean tissue mass using ob protein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE259243T1 true ATE259243T1 (de) | 2004-02-15 |
Family
ID=24243198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96938773T ATE259243T1 (de) | 1995-11-22 | 1996-11-04 | Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse |
| AT02011474T ATE455554T1 (de) | 1995-11-22 | 1996-11-04 | Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02011474T ATE455554T1 (de) | 1995-11-22 | 1996-11-04 | Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen |
Country Status (15)
| Country | Link |
|---|---|
| EP (3) | EP1285664B1 (https=) |
| JP (2) | JP4173914B2 (https=) |
| AT (2) | ATE259243T1 (https=) |
| AU (3) | AU7607496A (https=) |
| CA (2) | CA2236163A1 (https=) |
| DE (2) | DE69638119D1 (https=) |
| DK (1) | DK0866720T3 (https=) |
| ES (2) | ES2217327T3 (https=) |
| IL (2) | IL124442A0 (https=) |
| MX (1) | MX9803992A (https=) |
| NZ (3) | NZ511617A (https=) |
| PT (1) | PT866720E (https=) |
| SI (1) | SI0866720T1 (https=) |
| WO (1) | WO1997018833A1 (https=) |
| ZA (1) | ZA969605B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| PT866720E (pt) * | 1995-11-22 | 2004-06-30 | Amgen Inc | Proteina ob para aumentar a massa do tecido mole |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| EP0877627A1 (en) * | 1996-01-25 | 1998-11-18 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| AU2810497A (en) * | 1996-04-19 | 1997-11-12 | University Of Washington | Methods for inducing bone formation |
| CA2275183A1 (en) * | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| CA2274799A1 (en) * | 1996-12-20 | 1998-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| EP0950417A3 (en) | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
| AU3863699A (en) * | 1998-04-20 | 1999-11-08 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis with leptin |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| EP1128840A1 (en) * | 1998-10-27 | 2001-09-05 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
| AU781460B2 (en) * | 1999-02-12 | 2005-05-26 | Amgen, Inc. | Glycosylated leptin compositions and related methods |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| AU2002359288B2 (en) | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| CA2571292C (en) * | 2004-06-30 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| WO2008048691A2 (en) * | 2006-10-18 | 2008-04-24 | Amylin Pharmaceuticals, Inc. | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| RS58010B1 (sr) | 2012-09-27 | 2019-02-28 | Childrens Medical Ct Corp | Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| HUE063647T2 (hu) | 2016-09-12 | 2024-01-28 | Amryt Pharmaceuticals Inc | Eljárások anti-leptin semlegesítõ antitestek detektálására |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228925B (it) * | 1987-08-07 | 1991-07-10 | Eniricerche Spa | Procedimento per la preparazione dell'ormone della crescita umano |
| DK173142B1 (da) * | 1988-08-24 | 2000-02-07 | Natinco Nv | Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| CA2169351A1 (en) * | 1993-08-13 | 1995-02-23 | Martin Wanner | Process and device for treating the surface of large objects |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| PT866720E (pt) * | 1995-11-22 | 2004-06-30 | Amgen Inc | Proteina ob para aumentar a massa do tecido mole |
| IL124831A0 (en) * | 1995-12-27 | 1999-01-26 | Genentech Inc | Ob protein derivatives having prolonged half-life |
| CA2275183A1 (en) * | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| ATE223229T1 (de) * | 1997-04-17 | 2002-09-15 | Amgen Inc | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren |
-
1996
- 1996-11-04 PT PT96938773T patent/PT866720E/pt unknown
- 1996-11-04 SI SI9630675T patent/SI0866720T1/xx unknown
- 1996-11-04 NZ NZ511617A patent/NZ511617A/en not_active IP Right Cessation
- 1996-11-04 AU AU76074/96A patent/AU7607496A/en not_active Abandoned
- 1996-11-04 DE DE69638119T patent/DE69638119D1/de not_active Expired - Lifetime
- 1996-11-04 ES ES96938773T patent/ES2217327T3/es not_active Expired - Lifetime
- 1996-11-04 CA CA002236163A patent/CA2236163A1/en active Pending
- 1996-11-04 NZ NZ512083A patent/NZ512083A/xx not_active IP Right Cessation
- 1996-11-04 JP JP51974597A patent/JP4173914B2/ja not_active Expired - Fee Related
- 1996-11-04 EP EP02011474A patent/EP1285664B1/en not_active Expired - Lifetime
- 1996-11-04 NZ NZ527007A patent/NZ527007A/en not_active IP Right Cessation
- 1996-11-04 DE DE69631544T patent/DE69631544T2/de not_active Expired - Lifetime
- 1996-11-04 ES ES02011474T patent/ES2339846T3/es not_active Expired - Lifetime
- 1996-11-04 WO PCT/US1996/017718 patent/WO1997018833A1/en not_active Ceased
- 1996-11-04 EP EP98119160A patent/EP0956862A1/en not_active Withdrawn
- 1996-11-04 IL IL12444296A patent/IL124442A0/xx not_active IP Right Cessation
- 1996-11-04 EP EP96938773A patent/EP0866720B1/en not_active Expired - Lifetime
- 1996-11-04 DK DK96938773T patent/DK0866720T3/da active
- 1996-11-04 AT AT96938773T patent/ATE259243T1/de active
- 1996-11-04 CA CA002358862A patent/CA2358862A1/en not_active Abandoned
- 1996-11-04 AT AT02011474T patent/ATE455554T1/de not_active IP Right Cessation
- 1996-11-15 ZA ZA969605A patent/ZA969605B/xx unknown
-
1998
- 1998-05-20 MX MX9803992A patent/MX9803992A/es not_active IP Right Cessation
-
1999
- 1999-01-05 IL IL127926A patent/IL127926A/en not_active IP Right Cessation
-
2000
- 2000-06-23 AU AU42653/00A patent/AU763769B2/en not_active Ceased
- 2000-06-23 AU AU42652/00A patent/AU763755B2/en not_active Ceased
-
2001
- 2001-11-19 JP JP2001352728A patent/JP4227325B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE259243T1 (de) | Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse | |
| DK0733067T3 (da) | N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder | |
| GR3030141T3 (en) | Diphtheria toxin receptor-binding region. | |
| EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
| ATE458815T1 (de) | Homologe des nogo rezeptors | |
| BR9915679A (pt) | Composições e métodos para aumentar a mineralização óssea | |
| ATE267255T1 (de) | Ob proteinderivate mit verlängerter halbwertzeit | |
| BR9508467A (pt) | Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal | |
| HUP9901688A3 (en) | Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits | |
| DE69535274D1 (de) | Verwendung eines menschlichen interleukin-11 rezeptors | |
| EP0804562A4 (en) | CONTAINING TISSUE GROWTH FACTOR-2 | |
| DE69737651D1 (de) | Cortistatin: neuropeptide, zusammensetzungen und methoden | |
| ATE107859T1 (de) | Verwendung von antiprogestomimetika zur stimulierung des eisprungs. | |
| DE69735039D1 (de) | Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen | |
| SE9803962D0 (sv) | Nucleic acid encoding a nervous tissue sodium channel | |
| AU7079300A (en) | Compositions and methods for the treatment of immune related diseases | |
| MD899G2 (ro) | Procedeu de activizare a osteogenezei reparatorii | |
| SE9604439D0 (sv) | New receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0866720 Country of ref document: EP |